Resources
Whitepapers
Replacing clinical trials and registries
Data quality
Truveta Data comprises billions of EHR data points, representing more than 120 million patient journeys from more than 20,000 clinics and 900 hospitals, updated daily. Truveta Data adheres to the highest standards of quality and provenance, supported by stringent quality control processes detailed in this whitepaper. 
Truveta Language Model
Advancements in AI have presented a unique opportunity to transform and clean massive streams of healthcare data to make it available for research, innovation, and patient care. This whitepaper explains the Truveta Language Model, a large-language model used to clean billions of EHR data points for health research.
Accelerating research
The pace of research-driven medical progress has been slowed by difficulties in obtaining, cleaning, and analyzing clinical data. This whitepaper explores how Truveta Studio accelerates every step of the research process – from hypothesis to publication or regulatory submission – by providing immediate access to clean, high-quality, linked EHR data, powerful analytics, and AI.
Data security
Truveta’s advanced security systems protect Truveta Data through every stage of the data handling process and have been validated to meet the most rigorous standards for privacy and security. This whitepaper outlines how we manage the complex flow of health data to maintain customer and member health system trust.
Patient privacy
Founded by health systems, Truveta has a deep commitment to patient privacy. This whitepaper outlines how data flows from our health system members from the Truveta platform and the advanced measures taken to ensure patient privacy and protect against potential reidentification.
Powering device research
Medical device companies are challenged by a significant lack of real-world data on device use in clinical practice. In this whitepaper, learn how Truveta provides critical device specific information linked to deep clinical data to accelerate device research for over 150,000 unique medical devices.
Advancing cardiovascular research
Cardiovascular disease is a leading cause of death in the US, but researchers face many challenges when seeking to study the safety and effectiveness of drugs and devices used to treat it. This whitepaper highlights historical limitations of RWD and explains how Truveta addresses them to accelerate research on outcomes and care.
Truveta Mapper: A zero-shot ontology alignment framework
We share the technical details behind Truveta Mapper the underlying AI technology in the Truveta Language Model. Truveta Mapper leverages a multi-task sequence-to-sequence transformer model to perform alignment across multiple ontologies in a zero-shot, unified, and end-to-end manner. This paper was originally published at arXiv.
Ethics policy
We believe it is a moral imperative to harness the power of data to improve healthcare. We know we’ve taken on an enormous responsibility, and we pursue our work with a commitment to patient privacy, broadly enabling research and transparency about our data, all in close coordination with our member health systems.
Briefings
Oncology
Despite record investment in cancer research, many critical questions remain unanswered. Download this briefing to explore how Truveta Data is enabling more inclusive, timely, and actionable research on 100+ cancer types with over 7 million complete patient journeys.
Beyond trials: How real-world data is transforming autoimmune research
Truveta is advancing autoimmune disease research with the most representative, timely and complete real-world dataset available. Truveta enables life sciences companies to monitor therapy use, evaluate outcomes, and support regulatory decisions in a rapidly evolving treatment landscape.
How real-world data is unlocking health insights
Advancing cardiovascular device research with Truveta Data
Combating respiratory viruses with EHR data: Key use cases for life sciences and public health
EHR data is rapidly changing how life sciences, pharmaceutical, and public health organizations monitor and respond to respiratory viruses. With Truveta Data, researchers gain access to real-time insights into respiratory viruses like influenza, RSV, and COVID-19 through de-identified EHR data from over 120 million patients.
Clinical notes
Many research questions can’t be fully answered without the detailed insights hidden in clinical notes. Truveta unlocks data from over 5 billion notes and integrates these datapoints with semi-structured EHR data, enabling novel research on safety, effectiveness, and more.
How real-world data is transforming GLP-1 research for diabetes and obesity care
GLP-1 medications are revolutionizing the way we treat type 2 diabetes and obesity. With Truveta Data, researchers gain access to RWD that provides comprehensive insights, addressing critical questions about the real-world performance of GLP-1 therapies.
Transform the future of knee, hip, and shoulder replacements with device-level data
Standard outcomes data often limits orthopedic research to broad insights, such as overall success rates, average recovery times, or general complication rates. With Truveta, orthopedic researchers can access device-level insights and patient-reported outcomes from the most complete, timely, and clean regulatory-grade EHR data available.
10 reasons to choose Truveta’s mother-child EHR dataset
Understanding the link between maternal health and child outcomes is crucial for advancing both maternal and pediatric care. Truveta’s dataset includes daily updated data from over 1 million mother-child pairs, providing critical insights into how maternal health, behaviors, and exposures influence child outcomes.
Psoriasis data
Psoriasis is chronic, systemic disease that affects over 8 million people in the United States. Truveta’s complete, timely and clean EHR data includes a psoriasis patient population with over 4.3 million relevant notes. This briefing highlights the possibilities for psoriasis research with robust EHR data.
RWE for regulatory submissions
The FDA supports using real-world evidence for regulatory decision-making but stipulates that the underlying data must be fit for purpose. This briefing highlights Truveta’s approach to ensuring high-quality, fit-for-purpose EHR data and streamlining real-world evidence submissions to regulatory authorities.
Prostate cancer data
One in 8 men will develop prostate cancer, yet real-world datasets often fail to capture the full prostate cancer patient journey, early-stage treatments, and all treatment modalities. Truveta’s complete, longitudinal EHR data spans care settings and treatment types. This briefing highlights data available to support prostate cancer research and innovation.
Medical images
De-identified medical images are often hard to find and detached from clinical context, hindering research efforts. Truveta provides access to more than 85 million medical imaging studies integrated with complete EHR data. This briefing provides insight into the images available and how they’re advancing research.
Why TLM outperforms other LLMs
Unlocking the full potential of healthcare data has long been hindered by issues of fragmentation and lack of structure. The Truveta Language Model (TLM) offers a premier solution for normalizing EHR data at scale, enabling novel research. This briefing highlights what sets TLM apart from general large language models.
Linked EHR-SDOH data
Clinical care affects only 10-20% of modifiable health factors, while 80-90% are influenced by behaviors, socioeconomic factors, and the environment. This briefing highlights how integrating social drivers of health (SDOH) data into real-world data analyses offers precise insights on unmet needs, healthcare disparities, and therapy performance.
Echo data
Echocardiograms contain crucial clinical observations relevant for cardiovascular research, but obtaining these measures at scale for real-world data analysis has been a longstanding challenge. This briefing highlights how Truveta is normalizing and extracting echo observations at scale for research, and outlines data availability for specific measures.
Timeliness
Timely data are critical for life sciences and healthcare organizations, enabling innovation and high-quality patient care. However, most RWD sources have lags of weeks to months. This briefing focuses on Truveta’s real-time data and showcases the clinical questions it enables researchers to answer.
GLP-1 prescribing
GLP-1s, originally created to treat diabetes, have been found to suppress appetites and induce substantial weight loss in many patients. Extensive media coverage and celebrity endorsements have created overwhelming demand for these drugs, but little is known about real-world use. This briefing highlights findings from an analysis of first-time GLP-1 prescribing trends.
PAD treatment
Peripheral Artery Disease (PAD) is a common disease that causes the narrowing of the arteries in the extremities. As part of PAD Awareness month, Truveta Research investigated disparities in the frequency of common procedures used to treat PAD, known as endovascular (or minimally invasive) revascularization, and the associated outcomes.
Case studies and industry reports
Anti-seizure medications
Making data regulatory grade
Adoption of real-world evidence for regulatory decisions remains slower than necessary to meet growing industry demands. Truveta and Citeline surveyed life sciences leaders to uncover key barriers and opportunities for using real-world data in FDA submissions. This report highlights five critical insights from the survey and how Truveta is advancing regulatory-grade RWD.
Heart failure innovation
The lack of treatment evolution for heart failure (HF) is partly due to the difficulty and cost of studying complex inpatient interventions. This case study highlights how Reprieve Cardiovascular, a clinical-stage startup focused on decongestion for HF, partnered with Truveta to understand the current standard of care for HF to de-risk their pivotal clinical study and optimize trial protocols.
Assessing device safety
Despite promising clinical data for novel pulmonary embolism therapies, there are no randomized prospective studies comparing them and guidelines have not been updated to reflect real-world safety data. This case study showcases findings from a peer-reviewed study using Truveta Data to compare the safety of devices from Boston Scientific and Inari Medical.
Webinars
What’s really happening with GLP-1s?
See how real-time EHR data from over 120 million US patients, is accelerating insights on GLP-1 use and generating high-quality clinical evidence far faster than traditional trials.
Advancing pregnancy safety research
This on-demand webinar demonstrates how regulatory-grade EHR data from over 120 million patients, including clinical notes and images, can overcome challenges in studying underrepresented populations, like pregnant people.
EHR data to advance care
In this webinar replay, hear how Boston Scientific has leveraged Truveta Data to study device safety and utilization for peripheral artery disease and pulmonary embolism, and gain insight into how this type of information can be used to drive device innovation, advance health equity, and inform clinical guidelines.
Raising the bar on real-world data quality: ensuring regulatory-grade EHR data
Learn why researchers are betting on EHR data as the future of real-world evidence generation and what to look for when evaluating the quality of a real-world dataset.
Uncovering disparities in access to popular treatments: insights from linked EHR and SDOH data
Explore how linked EHR and SDOH data are accelerating the identification of health disparities for type 2 diabetes, Alzheimer’s disease, and heart disease treatments
Enabling timely comparative effectiveness research: head-to-head analysis of GLP-1s for weight loss
See the results of a real-world GLP-1 comparative effectiveness study and the impact of timely and representative RWD in assessing performance of new therapies.
Driving therapeutic innovation and de-risking clinical development: The power of RWD from EHRs
Speakers from Truveta, Reprieve Cardiovascular, The Permanente Medical Group, and Stanford Cardiovascular Medicine discuss how Truveta Data is being used to drive product innovation for acute heart failure.
Transforming clinical research: Scaling real-world data across diseases with expert-led AI
Hear from experts at UCB and Truveta as they demonstrate the power of Truveta’s AI-driven extraction of critical information from free text clinical notes to further research at UCB.
Advancing clinical research through unprecedented data and learning community for health
Partnering with Fierce Pharma, hear from an expert panel on the power of unprecedented data and what early patient insights have been unveiled.
Featured research
A time-series analysis of anxiety diagnoses and prescriptions from January 2018 to January 2023
medRxiv
https://doi.org/10.1101/2023.12.21.23300415
Time-series analysis of first-time pediatric speech delays from 2018 to 2022
JAMA Pediatrics
doi:10.1001/jamapediatrics.2023.5226
Comparative effectiveness of semaglutide and tirzepatide for weight loss in adults with overweight and obesity in the US: A real-world evidence study
medRxiv
doi: https://doi.org/10.1101/2023.05.18.23290122